Medtronic (Minneapolis) reported clinical trial results showing that heart failure patients treated with its exclusive AdaptivCRT feature experienced a nearly 50% reduction in atrial fibrillation (AF) risk. Pioneered by Medtronic, the AdaptivCRT technology is a feature on certain cardiac resynchronization therapy-defibrillators (CRT-Ds) designed to continually adjust therapy to a patient's natural heart rhythms and minimizes the amount of unnecessary right ventricular (RV) pacing. The results were presented Monday as a late breaking clinical trial at the Heart Failure Society of America's 17th annual scientific meeting in Orlando, Florida.